Welcome to our dedicated page for AC Immune news (Ticker: ACIU), a resource for investors and traders seeking the latest updates and insights on AC Immune stock.
AC Immune SA develops precision therapeutics and diagnostics for neurodegenerative diseases driven by misfolded proteins. The clinical-stage biopharmaceutical company uses its SupraAntigen® and Morphomer® platforms to advance active immunotherapies, small molecules, antibodies, vaccines and diagnostic programs for Alzheimer’s disease, Parkinson’s disease and NeuroOrphan indications.
Company news commonly covers clinical updates for ACI-24 in the ABATE Alzheimer’s disease study, ACI-7104.056 in the VacSYn Parkinson’s disease trial, ACI-19764 as an NLRP3 inflammasome inhibitor, and Tau Morphomer® small-molecule programs. Updates also include collaboration activity with global pharmaceutical partners, milestone payments, symposium presentations, financial results and cash runway disclosures.
AC Immune (NASDAQ: ACIU) received FDA Fast Track designation and IND clearance for its wholly owned anti‑alpha‑synuclein active immunotherapy ACI‑7104 to treat early-stage Parkinson’s disease. The candidate is being evaluated in the Phase 2 VacSYn trial, which will now expand to sites in the US.
According to AC Immune, interim Part 1 data at 76 weeks showed ACI‑7104 was safe and well tolerated, with no clinically relevant safety issues and a 100% responder rate for immunogenicity. A $4 million research grant supports extending Part 1 for two additional years, and full week‑100 results are expected in H2 2026.
AC Immune (NASDAQ: ACIU) reported first half 2026 results, highlighting progress in its wholly-owned neurodegeneration pipeline and strengthened partnering economics. Cash resources were CHF 75.4 million at June 30, 2026 (vs. CHF 91.4 million year-end 2025), expected to fund operations into Q4 2027, excluding future milestones.
Revenue rose to CHF 16.2 million from CHF 2.3 million, driven by the amended Lilly agreement (CHF 11.0 million) and Takeda collaborations (CHF 5.2 million). R&D expenses fell to CHF 22.2 million and G&A to CHF 7.7 million, reducing net loss to CHF 12.9 million (from CHF 40.2 million). Key updates included a $4 million grant for Phase 2 VacSYn (ACI-7104) in Parkinson’s disease, a $12 million milestone from Takeda for ACI-24’s AD4 cohort initiation, a CHF 10 million upfront from Lilly for the Morphomer Tau program, and anticipated H2 2026 readouts for ACI-7104 and ACI-19764. Long-time CEO Andrea Pfeifer retired, with Chair Martin Zügel appointed interim CEO.
AC Immune (NASDAQ:ACIU) will showcase its neurodegenerative disease pipeline with three presentations at AAIC 2026, held July 12-15 in London, UK.
The company will present data on a first-in-class TDP-43 PET tracer, a brain-penetrant NLRP3 inhibitor, and an alpha-synuclein aggregation inhibitor.
AC Immune (NASDAQ: ACIU) reported 12‑month interim data from the Phase 1b/2 ABATE trial of ACI‑24 in 74 patients with prodromal Alzheimer’s disease across cohorts AD1‑AD3.
According to AC Immune, ACI‑24 has been generally safe and well tolerated, with no ARIA‑E, and showed anti‑Abeta antibody responses at all dose levels with a dose response. A new AD4 cohort is testing an added adjuvant to enhance immunogenicity.
AC Immune (NASDAQ: ACIU) will receive a $4 million research grant from The Vijay and Marie Goradia Charitable Foundation to support development of ACI-7104 in early Parkinson’s disease.
The funding extends Part 1 of the Phase 2 VacSYn trial by 2 years to assess long-term safety and efficacy, with final week‑104 data expected in H2 2026. Interim results reported in December 2025 indicated a favorable safety profile, robust antibody responses, target engagement, and encouraging clinical signals.
AC Immune (NASDAQ: ACIU) reported new preliminary Phase 1 data for its first-in-class TDP-43 PET tracer ACI-19626, showing significantly higher tracer uptake in key brain regions of amyotrophic lateral sclerosis (ALS) patients versus healthy controls.
The tracer previously showed higher uptake in genetically defined frontotemporal dementia (FTD). ACI-19626 is described as safe and well tolerated, with rapid brain uptake and washout and dosimetry within accepted limits, supporting its potential use for human brain imaging and precision medicine approaches across TDP-43 proteinopathies.
AC Immune (Nasdaq: ACIU) announced that co-founder and CEO Dr Andrea Pfeifer will retire at the upcoming AGM after 23 years. Board Chair Dr Martin Zügel will become interim CEO while a search firm leads the process for a permanent successor.
Dr Pfeifer will remain as Advisor, Honorary Chair of the Board, and Co-Chair of the Scientific Advisory Board. AC Immune highlights a robust balance sheet, three Precision Prevention candidates for Alzheimer’s and Parkinson’s in the clinic, and partnerships with Eli Lilly, Takeda and Johnson & Johnson.
AC Immune (NASDAQ: ACIU) reported Q1 2026 corporate and clinical updates and cash resources of CHF 74.8 million as of March 31, 2026, providing runway into Q4 2027. Key program moves: dosing started in Phase 1 of the brain-penetrant NLRP3 inhibitor ACI-19764, final ABATE cohort AD4 initiated (triggers $12M payment), and an amended Morphomer Tau deal with Lilly includes a CHF 10M upfront payment.
Anticipated 2026 readouts include ABATE 12-month interim data (H1), Part 1 VacSYn final data (H2), and Phase 1 ACI-19764 results (H2).
AC Immune (NASDAQ: ACIU) dosed the first patient in Cohort AD4 of the Phase 1b/2 ABATE trial and triggered a $12 million milestone from Takeda. AD4 will enroll 36 patients for 12 months (plus 6-month follow-up) and could expand to ~112 patients. 12-month data from AD1–AD3 are expected in Q2 2026. Under the Takeda agreement, AC Immune received a $100 million upfront payment and is eligible for up to $2.1 billion in further milestones and tiered double-digit royalties on sales.
AC Immune (NASDAQ: ACIU) amended its 2018 Morphomer Tau license and collaboration with Eli Lilly to advance orally bioavailable Tau aggregation inhibitor small molecules.
The amendment includes a CHF10 million upfront payment, an additional Phase 1 dosing milestone, IND-enabling studies starting H1 2026, eligibility for >CHF1.7 billion in milestones, and low double-digit tiered royalties.